MedTrace Logo

Severity of Sarcopenia in Parkinson's Disease

NCT07014514 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 65

Last updated 2026-03-25

No results posted yet for this study

Summary

This study aimed to determine the prevalence of sarcopenia and dynapenia in Parkinson's disease patients, classified into early-stage (\<2.5) and moderate-stage (≥2.5) according to the Modified Hoehn and Yahr scale, and healthy controls using the ICF-based ISarcoPRM algorithm, and to examine the differences in regional muscle morphology, muscle strength, and physical performance between groups.This study was conducted as a cross-sectional research. The study included 43 Parkinson's disease patients aged 50-75 years, classified as stages 1-3 according to the Modified Hoehn-Yahr Scale, and 22 healthy individuals with similar demographic characteristics. Parkinson's disease patients were divided into two subgroups according to the Modified Hoehn-Yahr Scale: early stage (\<2.5) and intermediate stage (≥2.5). Demographic information of all participants was recorded, and clinical evaluations were performed. Parkinson's disease staging was assessed using the Modified Hoehn-Yahr Scale. Muscle mass was assessed using ultrasonography to measure anterior femoral muscle thickness. Muscle strength was measured by handgrip strength, and physical performance was assessed using a five-count sit-up test.

Conditions

  • Parkinson Disease

Sponsors & Collaborators

  • Ankara University

    lead OTHER

Principal Investigators

  • Süleyman Korkusuz, PhD · Atılım University

  • Ayla Fil Balkan, Assoc Prof · Hacettepe University

  • Gül Yalçın Çakmaklı, Assoc Prof · Hacettepe University

  • Büşra Seçkinoğulları Korkusuz, PhD · Ankara University

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-06-20
Primary Completion
2025-09-20
Completion
2025-10-25

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07014514 on ClinicalTrials.gov